Multitargeted Effects of Statin-Enhanced Thrombolytic Therapy for Stroke With Recombinant Human Tissue-Type Plasminogen Activator in the Rat | Zendy

Li Zhang | Zendy; Zheng Gang Zhang | Zendy; Guangliang Ding | Zendy; Quan Jiang | Zendy; Xianshuang Liu | Zendy; He Meng | Zendy; Ann Hozeska | Zendy; Chunling Zhang | Zendy; Lian Li | Zendy; Dan Morris | Zendy; Rui Lan Zhang | Zendy; Mei Lü | Zendy; Michael Chopp | Zendy

Open Access

Multitargeted Effects of Statin-Enhanced Thrombolytic Therapy for Stroke With Recombinant Human Tissue-Type Plasminogen Activator in the Rat

Author(s) -

Li Zhang,

Zheng Gang Zhang,

Guangliang Ding,

Quan Jiang,

Xianshuang Liu,

He Meng,

Ann Hozeska,

Chunling Zhang,

Lian Li,

Dan Morris,

Rui Lan Zhang,

Mei Lü,

Michael Chopp

Publication year - 2005

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.104.516757

Subject(s) - medicine , plasminogen activator , recombinant dna , t plasminogen activator , stroke (engine) , recombinant tissue plasminogen activator , statin , pharmacology , tissue plasminogen activator , activator (genetics) , cardiology , ischemic stroke , receptor , ischemia , biochemistry , mechanical engineering , engineering , chemistry , modified rankin scale , gene

Microvascular dysfunction posttreatment of stroke with recombinant human tissue-type plasminogen activator (rht-PA) constrains the therapeutic window to 3 hours. Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) promote vascular thrombolysis and reduce the inflammation response. We therefore investigated the neuroprotective effects of a combination of atorvastatin and delayed rht-PA treatment in a rat model of embolic stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research